Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

Brings 20+ years of expertise in finance and enterprise operations at each private and non-private life sciences firms

BURLINGTON, Mass., January 11, 2024–(BUSINESS WIRE)–Bone Biologics Company (“Bone Biologics” or the “Firm”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic merchandise for spine fusion markets, at present introduced that efficient instantly Robert E. Gagnon has been named to the Firm’s board of administrators. Mr. Gagnon fills the seat left by Erick Lucera, who has resigned efficient upon Mr. Gagnon’s appointment. The variety of administrators of Bone Biologics stays at 4.

Mr. Gagnon is at present chief monetary officer of Remix Therapeutics, a medical stage firm centered on small molecule-mediated reprogramming of RNA processing to handle hard-to-drug illness drivers.

“We’re delighted {that a} skilled of Rob’s stature has agreed to hitch our board of administrators,” stated Jeffrey Frelick, president and chief government officer of Bone Biologics. “He has supported the expansion of so many profitable firms and we look ahead to Rob’s counsel. His experiences with medical stage firms, capital elevating, and business organizations will likely be notably useful as we undertake our pilot research with NB-1.”

Mr. Gagnon brings greater than 20 years of monetary and business expertise main world finance operations. He served as an Working Accomplice at Gurnet Level Capital, a healthcare enterprise capital and personal fairness fund. He was Chief Enterprise Officer and Chief Monetary Officer at Verastem Oncology. Earlier than that, he was Chief Monetary Officer at Harvard Bioscience, Inc. Mr. Gagnon served as Government Vice President, Chief Monetary Officer, and Treasurer at Clear Harbors, Inc. in addition to Chief Accounting Officer and Controller at Biogen Idec, Inc. Mr. Gagnon labored in quite a lot of senior positions at Deloitte & Touche, LLP, and PricewaterhouseCoopers, LLP. He holds an MBA from the MIT Sloan College of Administration and a BA in Accounting from Bentley Faculty.

Mr. Gagnon at present serves on the Board of Administrators at Verastem Oncology and Purple Biotech.

About Bone Biologics
Bone Biologics was based to pursue regenerative drugs for bone. The Firm is endeavor work with choose strategic companions that builds on the preclinical analysis of the Nell-1 protein. Bone Biologics is focusing growth efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, whereas moreover having rights to trauma and osteoporosis purposes. For extra info, please go to www.bonebiologics.com.

Ahead-Trying Statements
Sure statements contained on this press launch, together with, with out limitation, statements concerning the anticipated outcomes and efficiency of Mr. Gagnon with the Firm and the anticipated timing of enrollment in our pilot research with NB-1, in addition to statements containing the phrases “will,” “put together,” and phrases of comparable import, represent “forward-looking statements” inside the which means of the Non-public Securities Litigation Reform Act of 1995. Such forward-looking statements contain each identified and unknown dangers and uncertainties. The Firm’s precise outcomes could differ materially from these anticipated in its forward-looking statements on account of a variety of components, together with, however not restricted to, market and different situations and dangers typically related to an undercapitalized growing firm, in addition to the dangers contained below “Threat Elements” and “Administration’s Dialogue and Evaluation of Monetary Situation and Outcomes of Operations” within the Firm’s Annual Report on Type 10-Ok for the yr ended December 31, 2022 and the Firm’s different filings with the Securities and Change Fee. Besides as required by relevant legislation, we undertake no obligation to revise or replace any forward-looking statements to replicate any occasion or circumstance that will come up after the date hereof.